By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roched has entered into an agreement with ChanTest to evaluate the safety of potential drug compounds.

Under the terms of the deal announced today, ChanTest, an ion channel screening provider, will use Roche's xCelligence System RTCA Cardio Instrument and Cellular Dynamics International's iCell Cardiomyocytes to evaluate pharmacological responses to a number of compounds that have been selected based on their known effects on ion channels.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.